DEFA14A: Veru Inc. Announces Date of 2024 Annual Meeting of Shareholders; Files Updated Financial Reports

Veru Inc. has set its 2024 Annual Meeting of Shareholders for June 18, 2024, following the filing of its 2023 Form 10-K/A and Q1 2024 Form 10-Q.

Summary

• Veru Inc., a biopharmaceutical company, announced its Annual Meeting of Shareholders will be held on June 18, 2024.
• The announcement follows the filing of the company's amendment to its Annual Report on Form 10-K/A for the year ended September 30, 2023, and its Quarterly Report on Form 10-Q for the three months ended December 31, 2023.
• The company intends to file an amendment to its definitive proxy statement to reflect the rescheduled meeting date and new record date.
• Veru is focused on developing medicines for metabolic diseases, oncology, and ARDS, with key programs including enobosarm and sabizabulin.
• Enobosarm is in Phase 2b clinical study for treating muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA and, subject to funding, a Phase 3 trial for metastatic breast cancer.
• Sabizabulin is being developed for viral-induced ARDS, but further development is contingent on securing external funding.
• A Phase 2b clinical trial for enobosarm is expected to begin in April 2024, with topline results expected by the end of the year; an extension trial's results are expected in Q2 2025.

Sentiment

Score: 6

Explanation: The announcement is neutral, primarily focused on administrative updates and clinical trial plans. The dependence on external funding for sabizabulin introduces some uncertainty.

Positives

• The company has completed the filings necessary to hold the Annual Meeting of Shareholders.
• Enobosarm has shown promise in preserving muscle mass and reducing fat mass in previous clinical trials.
• The Phase 2b clinical trial for enobosarm has received FDA clearance and is expected to begin in April 2024.

Negatives

• Further development of sabizabulin for viral-induced ARDS is contingent on securing external funding, which introduces uncertainty.
• The Phase 3 ENABLAR-2 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting is subject to the availability of sufficient funding.

Risks

• The success of the enobosarm clinical trials is subject to known and unknown risks, uncertainties, and assumptions.
• The company's actual results could differ materially from those expressed or implied by forward-looking statements.
• The company's ability to secure external funding for sabizabulin development is uncertain.

Future Outlook

The company is focused on advancing its clinical programs for enobosarm and sabizabulin, with the goal of developing novel medicines for metabolic diseases, oncology, and ARDS. The company expects topline data from the Phase 2b enobosarm trial by the end of 2024 and from the extension trial in Q2 2025.

Industry Context

Veru is operating in the competitive biopharmaceutical industry, focusing on developing treatments for metabolic diseases, oncology, and ARDS. The company's focus on enobosarm for muscle preservation in obesity patients aligns with the growing market for weight loss drugs, particularly GLP-1 receptor agonists. The company's strategy to seek external funding for sabizabulin development reflects the challenging funding environment for clinical-stage biopharmaceutical companies.

Comparison to Industry Standards

• Enobosarm, as a selective androgen receptor modulator (SARM), is being developed for muscle preservation, a strategy similar to other companies exploring therapies to mitigate muscle loss associated with weight loss drugs.
• The Phase 2b clinical trial design for enobosarm, including endpoints such as lean body mass and total body fat mass, aligns with industry standards for evaluating weight loss and body composition changes.
• The company's approach to seeking external funding for sabizabulin development is common in the biopharmaceutical industry, particularly for programs with uncertain commercial potential or high development costs.

Stakeholder Impact

• Shareholders will be able to vote on company matters at the Annual Meeting.
• The clinical trial results for enobosarm could impact the company's stock price and future prospects.
• The availability of funding for sabizabulin development will affect the company's ability to pursue this program.

Next Steps

• File an amendment to the definitive proxy statement for the Annual Meeting.
• Mail a new notice of the Annual Meeting and proxy card to all shareholders.
• Commence the Phase 2b clinical trial for enobosarm in April 2024.
• Continue seeking external funding for sabizabulin development.

Key Dates

Keywords

Annual Meeting, Enobosarm, Sabizabulin, Clinical Trial, Biopharmaceutical, Veru Inc., Shareholders, Form 10-K/A, Form 10-Q